RxDoctor Payments Data

Glenn Mizrach, MD

Family Medicine · Richmond, VANPI 1437158128

Payments from drug & device makers

$6,856in general payments, 2019–2025

Across 467 payments — averaging $14.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$819
  • AbbVie$796
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$724
  • Lilly USA, LLC$644
  • AstraZeneca$630
  • Amarin Pharma, Inc.$619
  • plus $3K from 36 others

What the payments were for

  • Speaking & faculty fees$751%
  • Food & beverage$6,77599%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,856 in reported general payments places this provider in the 90th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$99,895
Medicare patients
291
Services billed
1,965

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide109$136,311
JardianceEmpagliflozin142$122,986
TrulicityDulaglutide96$97,823
EliquisApixaban38$33,732
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$32,853
MounjaroTirzepatide18$18,926
FarxigaDapagliflozin Propanediol23$18,036
Breo ElliptaFluticasone/Vilanterol40$15,621
JanuviaSitagliptin Phosphate13$12,364
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr19$8,860
Atorvastatin Calcium589$4,630
Lantus SolostarInsulin Glargine,hum.Rec.Anlog33$3,953
Amlodipine Besylate538$2,718
Albuterol Sulfate HfaAlbuterol Sulfate135$2,627
DilantinPhenytoin Sodium Extended11$2,276

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$819$136,311109 claims
Boehringer IngelheimJardiance$338$122,986142 claims
Lilly USA, LLCTrulicity, Mounjaro, Humulin 70-30$644$117,696125 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$468$57,33497 claims
PfizerEliquis, Dilantin, Paxlovid$364$37,43870 claims
AstraZenecaFarxiga$630$18,03623 claims
MerckJanuvia$12$12,36413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →